A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.

ABSTRACT:

Purpose

Although adoptive cell therapy can be highly effective for the treatment of patients with melanoma, the application of this approach to the treatment of other solid tumors has been limited. The observation that the cancer germline (CG) antigen NY-ESO-1 is expressed in 70% to 80% and in approximately 25% of patients with synovial cell sarcoma and melanoma, respectively, prompted us to perform this first-in-man clinical trial using the adoptive transfer of autologous peripheral blood mononuclear cells that were retrovirally transduced with an NY-ESO-1-reactive T-cell receptor (TCR) to heavily pretreated patients bearing these metastatic cancers.

Experimental design

HLA-*0201 patients with metastatic synovial cell sarcoma or melanoma refractory to standard treatments an

SUBMITTER: Robbins PF 

PROVIDER: S-EPMC4361810 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature